Background
Abstract Background
Oral squamous cell carcinoma (OSCC) is a global healthcare problem associated with poor patient outcomes. Early detection is key to improving patient survival.
OSCC may be preceded by clinically-recognisable lesions, termed oral potentially malignant disorders (OPMD). As histological assessment of OPMD does not accurately predict their clinical behaviour, biomarkers are required to detect cases at risk of malignant transformation. Epidermal growth factor receptor gene copy number (EGFR GCN) is a validated biomarker in lung non-small cell carcinoma. We examined EGFR GCN in OPMD and OSCC to determine its potential as a biomarker in oral carcinogenesis.
Methods

EGFR GCN was examined by in situ hybridisation (ISH) in biopsies from 78 patients
with OPMD and 92 patients with early-stage (stages I and II) OSCC. EGFR ISH signals were scored by two pathologists and a category assigned by consensus. The data were correlated with patient demographics and clinical outcomes.
Results
OPMD with abnormal EGFR GCN were more likely to undergo malignant transformation than diploid cases. EGFR genomic gain was detected in a quarter of early-stage OSCC, but did not correlate with clinical outcomes.
Conclusion
These data suggest that abnormal EGFR GCN has clinical utility as a biomarker for the detection of OPMD destined to undergo malignant transformation. Prospective studies are required to verify this finding. It remains to be determined if EGFR GCN could be used to select patients for EGFR-targeted therapies.
Introduction
Oral squamous cell carcinoma (OSCC) is a major healthcare problem and is associated with poor clinical outcomes. Approximately 50% of patients diagnosed with OSCC die prematurely as a consequence of the disease (1, 2) . Outcomes for patients with OSCC may be improved if the disease is identified in its earliest stages (3) . OSCC formation occurs through the stepwise accumulation of genetic damage (4, 5) . OSCC may be preceded by clinically-recognisable lesions termed oral potentially malignant disorders (OPMD) (6). However, the histological features of OPMD do not reliably predict their clinical behaviour (7, 8) . There is consequently a need to develop biomarkers that enhance prognostication and direct treatment (9).
Epidermal growth factor receptor (EGFR) gene copy number (GCN) is used in the prognostication of non-small cell lung carcinoma (10, 11) and the prediction of its response to EGFR-targeted chemotherapeutic agents (12) . The potential of EGFR as a biomarker in OSCC was first highlighted in the early 1990s (13) . EGFR is a cell surface tyrosine kinase receptor, one of four proteins in the ErbB family, and is expressed in most epithelial tissues (14) . Binding of growth factors (e.g. epidermal growth factor and transforming growth factor-α) to the extracellular domain induces a conformational change in the internal receptor (15, 16) . Subsequent phosphorylation of intracellular substrates triggers a myriad of downstream signalling cascades (17) .
In OSCC, these contribute to an increase in cell proliferation, angiogenesis, invasion, and metastasis, which are the hallmarks of cancer (18, 19) . EGFR genomic gain is associated with poor clinical outcomes in OSCC (20) (21) (22) . The prevalence of EGFR genomic gain in OSCC ranges from 9% to 56% (23) (24) (25) (26) and is more frequent in Stage III/IV disease, suggesting that EGFR genomic gain is a late event in oral carcinogenesis. By contrast, data from two OPMD studies show that cases with low polysomy are more likely to progress to OSCC (27, 28) . These data suggest that EGFR GCN starts to increase in the early stages of oral carcinogenesis and raise the possibility that it could be used as a biomarker of malignant transformation. However, both studies were limited by small samples sizes and analysis of tissue microarrays rather than whole sections. Furthermore, low polysomy is not regarded as EGFR genomic gain in the criteria currently validated 7 for interpretation of non-small cell lung carcinoma as only high polysomy/clustered EGFR GCN signals are reported to correlate significantly with clinical outcome and response to EGFR-targeted therapy (10, 11) . Consequently, the biological significance of EGFR low polysomy is uncertain, particularly given the complexity of the EGFR signalling pathway (29, 30).
The aims of this study were:
• to determine the frequency of EGFR GCN abnormalities in patients with OPMD and early-stage OSCC.
• to correlate EGFR GCN abnormalities with clinico-pathological data and patients' clinical outcomes.
• to determine EGFR protein expression in OPMD and early-stage OSCC in order to gauge the likely functional significance of EGFR GCN changes.
Materials and Methods
Patients
Cases of OPMD that did not transform to OSCC were identified from a group of patients attending a hospital-based OPMD clinic. These cases had a minimum of 24 months' follow up.
Cases of OPMD that underwent malignant transformation were identified using a systematic search of the electronic archives using SNOMED codes. The search spanned a 12-year period (1997 -2009 ). The subsequent OSCC was also identified and retrieved for analysis. Clinical follow-up data were obtained from medical records.
Consecutive local cases of early-stage (pStage I/II) OSCC were identified by searching hospital databases and latterly the DAHNO (DAta on Head and Neck Oncology) UK database. The search spanned an 8-year period (2000 -2008) .
Cases with the following characteristics were excluded: 1) previous upper aerodigestive tract cancer; 2) previous radiotherapy to the head and neck region; 3) index lesions arising on the lip or in the oropharynx; 4) <24 months' follow-up; 5) <6 8 months between index OPMD biopsy and OSCC diagnosis; 6) proliferative verrucous leukoplakia; 7) non-dysplastic OPMD diagnosed with specific clinicopathological entities, e.g. chronic hyperplastic candidosis and lichen planus.
For each case, patient demographic data (sex, age at first biopsy) and mucosal subsite of the OPMD/OSCC were recorded. For OPMD, the clinical outcome (i.e. whether or not the lesion underwent malignant transformation to OSCC) was recorded. For OPMD that underwent malignant transformation, time from diagnosis of OPMD to developing OSCC was calculated. For early-stage OSCC, the histological grade of differentiation (Broders' classification) was determined and clinical outcomes (disease-free survival, overall survival) were calculated.
Pathology methods
Haematoxylin and eosin (H&E) stained sections and formalin-fixed paraffinembedded tissue blocks were retrieved for each case to confirm the presence of disease and adequacy of material for subsequent analysis. For OPMD epithelial dysplasia was graded independently by two pathologists (MR & PS) using a binary system (low-grade vs. high-grade) (7, 8). Discordant cases were reviewed and a grade was assigned by consensus.
EGFR in situ hybridisation
EGFR GCN was assessed by a dual-colour in situ hybridisation (ISH) technique using proprietary reagents (INFORM EGFR-Chromosome 7 dual colour assay, Ventana Medical Systems Inc, USA). This detects the EGFR gene (using silver ISH, seen as black nuclear dots) and chromosome 7 centromeres (using Ultraview Alkaline Phosphatase Red ISH, seen as red nuclear dots) on the same section. 4 µm sections were stained using the Ventana Benchmark Autostainer according to the manufacturer's instructions. Negative controls (with DNA probes omitted) were performed for each staining batch.
Dual-stained ISH sections were examined by two pathologists (TB & MR) and a category was assigned by consensus. According to the predominant nuclear signal, each case was assigned to one of the six categories described and validated by the manufacturers for the interpretation of non-small cell lung carcinoma ( Figure 1 ) (31).
Dividing cells and overlapping cells were not assessed. During analyses, the six 9 descriptive categories were reduced to three groups for comparison: normal, low polysomy, and genomic gain ( Figure 1 ) and also analysed in a binary classification: normal vs. abnormal EGFR GCN.
EGFR immunohistochemistry
EGFR protein expression was detected using a proprietary antibody (anti-EGFR 5B7 clone, Ventana Medical Systems Inc, USA). 4 µm sections were stained using a Ventana Benchmark Autostainer according to the manufacturer's instructions.
Morphologically normal epithelium provided an internal control for each section.
Negative controls (primary antibody omitted) were performed for each staining batch.
EGFR-stained slides and corresponding H&E sections were scanned using the Aperio Scanscope platform (x400 magnification). Files were uploaded to and analysed using the Aperio Spectrum image analysis system (Spectrum Version 11.1.0.751, Aperio Technologies, Inc.). H&E sections were used to map areas of normal epithelium, epithelial dysplasia and OSCC on corresponding EGFR-stained section. Representative areas were annotated and analysed using the Aperio cellular algorithm. The algorithm generated data for a range of parameters including the number of cells analysed, the proportion of positive cells, and the proportion of strongly-positive cells. Data were collated in an Excel file prior to statistical analysis.
Statistical analysis
Statistical analysis was performed using SPSS for Windows (version 21.0; SPSS Inc., Chicago, Illinois, USA). Following a test of normality, parametric data were analysed using one-way ANOVA/independent sample T-tests, and non-parametric data using Kruskal-Wallis/Mann-Whitney U-tests. A Bonferroni correction was applied to multiple comparisons. Time-to-event analyses were plotted using KaplanMeier curves and assessed using Log Rank (Mantel-Cox) calculations. Receiveroperator curves (ROC) were generated by plotting true positive rates against the false positive rates. Prior to analysis, cases were classified into binary groups analysed using Pearson's Chi-squared test. Results were considered significant at p<0.05.
Ethical approval
The study had a favourable ethical opinion from the National Research Ethics Service (NRES) Committee North East, Sunderland (REC reference: 11/NE/0118).
Results
Patient characteristics and clinical outcomes
A total of 78 OPMD and 92 OSCC cases satisfied the study inclusion criteria. Mean ages for these two groups were 58.6 (range 30 -94) and 61. For OPMD, the histological grade of epithelial dysplasia showed a significant correlation with clinical outcome. Cases with high-grade epithelial dysplasia were more likely to undergo malignant transformation than cases with low-grade epithelial dysplasia (p<0.05, Figure 2A ).
EGFR in situ hybridisation
Nuclei in normal epithelium adjacent to OPMD or OSCC consistently showed disomy, the normal EGFR ISH signal ( For statistical analysis, the 15 OPMD with low polysomy were combined with the one case of EGFR genomic gain to form a single 'abnormal EGFR GCN' group (n = 16).
Kaplan-Meier time-to-event analysis demonstrated a statistically significant correlation between abnormal EGFR GCN and malignant transformation (p<0.0001, Figure 2B ). Comparison using receiver-operator curve (ROC) analysis confirmed that abnormal EGFR GCN was a more reliable predictor of malignant transformation than high-grade epithelial dysplasia (Figure 4) . A combined category (cases with both abnormal EGFR GCN and high-grade epithelial dysplasia) showed similar KaplanMeier curves to EGFR GCN alone ( Figure 2C ) and the ROC profile was identical (data not shown).
OSCC arising from OPMD cases
Twenty-two OPMD cases underwent malignant transformation to OSCC. Biopsy material was available for 21 of these cases. EGFR genomic gain was detected in nearly one-quarter of the associated OSCC (5 cases, 24.0%). One-third of the associated OSCC showed low polysomy (7 cases, 33.3%). The associated OSCC generally either maintained the low polysomy of the OPMD, or showed progression to EGFR genomic gain. The EGFR GCN categories of the transforming OPMD and associated OSCC are shown in Figure 5 .
Early-stage OSCC
EGFR genomic gain was identified in 23 (24.7%) early-stage OSCC (11 showed high polysomy and 12 showed clusters). EGFR genomic gain was associated with a reduction in mean overall survival time (50.2 months vs. 57.7 months for cases with no genomic gain) and disease-free survival (45.6 months vs. 47.7 months for cases with no genomic gain); however, neither trend was statistically significant (p=0.201 and p=0.472, respectively). EGFR genomic gain did not correlate with tumour grade, recurrence or lymph node metastasis (data not shown).
EGFR protein expression
OPMD
Areas of epithelial dysplasia showed significantly higher mean EGFR protein 
OSCC arising from OPMD cases
The OSCC associated with the transformed group of OPMD showed significantly higher mean EGFR protein expression than normal epithelium (p<0.0001, Independent T-test).
Early-stage OSCC
Early-stage OSCC had significantly higher mean EGFR protein expression than normal epithelium ( Figure 6) 
Discussion
There is a continuing need for biomarkers that refine morphological diagnoses and inform clinical decisions for patients with OPMD and OSCC (9). EGFR GCN is used in the prognostication of non-small cell lung carcinoma (10, 11) and to predict response to EGFR-targeted chemotherapeutic agents (12) . Over recent years, EGFR GCN has emerged as a potential biomarker for OPMD and OSCC (30, 32).
However, the prevalence and clinical significance of EGFR GCN abnormalities in OPMD and OSCC are not well defined (20, 21, 33, 34) . Furthermore, it is unclear how criteria validated for interpretation of EGFR GCN signals in non-small cell lung carcinoma should be applied to oral cancer. It is well-documented that detection of high-risk human papillomavirus (HPV) by p16 immunohistochemistry (IHC) and in situ hybridisation (ISH) is significant in the prognostication of oropharyngeal squamous cell carcinoma (35-37). The current study was restricted to the examination of potentially malignant disorders/squamous cell carcinoma of the oral cavity and excluded oropharyngeal subsites. Consequently, we would only expect a very small number of cases to harbour oncogenic HPV infection, less than 5% (38, 39) . HPV status was therefore unlikely to influence the results of our study.
One-fifth of OPMD in the present study showed an abnormal EGFR GCN, but only one case showed evidence of EGFR genomic gain according to the criteria validated for non-small cell lung cancer. This is consistent with data from studies of EGFR GCN in OSCC, which indicate that EGFR genomic gain is a late event in oral carcinogenesis (23) (24) (25) . It is striking, however, that the majority of OPMD with low polysomy progressed to OSCC. This finding is consistent with two recent studies that suggest low polysomy is an early feature of OPMD destined to undergo malignant transformation, one which heralds EGFR genomic gain later in oral carcinogenesis (27, 28) . Both studies used fluorescence ISH (FISH) rather than the chromogenic ISH (CISH) technique used in the current study. Benchekroun et al (27) showed EGFR genomic gain, any increase in EGFR GCN was strongly associated with an increased risk of malignant transformation, irrespective of whether the EGFR GCN increase was low or high; increased EGFR GCN was also associated with a reduced time to malignant transformation (28). Together, these studies suggest that EGFR GCN may have some clinical utility in the risk management of OPMD, but is not sufficiently predictive to be used as a standalone biomarker.
Although the frequency of EGFR mutations documented in OSCC is low (40) (41) (42) , it is a limitation of the current study that neither EGFR mutation status nor downstream EGFR targets were evaluated. It is possible that EGFR GCN represents a 'surrogate' marker for other genetic and molecular abnormalities and simply reflect chromosomal instability; nevertheless, the positive correlation between EGFR GCN and protein over-expression suggests that increased EGFR GCN may be functionally relevant. Data from the group of OSCC that transformed from OPMD provide some evidence to support this hypothesis: the majority of these OSCC either maintained the abnormal EGFR GCN of the index OPMD or progressed to EGFR genomic gain, suggesting that EGFR genetic abnormalities accumulate during oral carcinogenesis. Interestingly, however, two cases of OPMD with abnormal EGFR GCN produced OSCC with a normal EGFR ISH signal. This may reflect clonal evolution of carcinoma from malignant cells with normal EGFR GCN; alternatively, it may simply represent tumour heterogeneity and the consequent limitations of sampling.
A quarter of OSCC in the present study showed EGFR genomic gain. This finding was consistent across both the early-stage and transformed OSCC groups. It is higher than the 9% rate reported in a tissue-microarray study by Rössle et al (24) . This earlier study also focused on early-stage (stage I/II) OSCC; however, it was limited by assessment of 0.6mm diameter tissue cores. It is our experience that the EGFR ISH pattern in OSCC is heterogeneous; tissue microarray sampling may therefore not correlate with measurements taken from whole sections.
Notwithstanding these issues, however, the proportion of cases with EGFR genomic gain in the current study is towards the lower end of the range of values reported to date (range 9% to 56%) (23) (24) (25) (26) . Our study did not identify a significant correlation between EGFR genomic gain and clinical outcome in OSCC, which is similar to two recent studies (24, 43) . By contrast, Temam et al (20) reported a 9% 5-year survival rate for patients with EGFR genomic gain compared with 71% 5-year survival rate for patients with no genomic gain. Although the study used quantitative real-time PCR, its findings have been corroborated by other studies using FISH (21, 23) . This apparent discrepancy may reflect the inclusion of late-stage OSCC in these previous studies; our study differed in its focus on the transition from OPMD to OSCC and assessment of early-stage OSCC.
Our data confirm that EGFR protein expression is increased in the majority of OPMD and OSCC (44-46 
Figure 4
Receiver-operator curve analysis of malignant transformation for high-grade epithelial dysplasia and abnormal EGFR gene copy number
Red line: abnormal EGFR gene copy number. Green line -high-grade epithelial dysplasia.
Black line -reference line.
The table beneath the chart summarises the differences between the two curves. The greater the area beneath the curve, the greater the predictive reliability of the marker. The area beneath the curve for abnormal EGFR GCN was greater than the area for high-grade epithelial dysplasia. This indicates that abnormal EGFR GCN was more reliably predictive of malignant transformation than high-grade epithelial dysplasia. This is further borne out by comparison of the asymptotic significance of the two tests: only abnormal EGFR GCN is significant at p<0.05.
Figure 5 EGFR GCN of OPMD that underwent malignant transformation and their associated OSCC
Green -normal GCN; amber -low polysomy; red -genomic gain.
Figure 6
Comparison of EGFR protein expression for normal epithelium,
OPMD and early stage OSCC
Areas of epithelial dysplasia and early-stage OSCC had significantly higher EGFR expression than normal epithelium (p<0.001 and p<0.0001 respectively). OPMD with highgrade epithelial dysplasia had significantly higher levels of EGFR than OPMD with low-grade epithelial dysplasia (p<0.0001). There were no significant differences in the EGFR protein expression of OPMD that underwent malignant transformation and those which did not (p>0.05). The error bars show the standard error of the mean. 
